Methotrexate has long been a cornerstone of therapy in rheumatoid arthritis. Two new, injectable methotrexate products may help some RA patients for whom oral methotrexate is not as effective or causes adverse effects. Rasuvo and Otrexup are prefilled, auto-injection devices that allow patients to give themselves subcutaneous injections of methotrexate without having to use a…
NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…
Review of clinical research on methotrexate therapy, effect on patients’ functionality, tolerability, adverse events
Data suggest changes in physiology of the gut post-bariatric surgery may result in medication malabsorption of immunosuppressive drugs
Plus, rheumatology drug news, safety updates
A secondary review
By regulating molecules key to osteoclast/osteoblast processes, methotrexate may reduce bone destruction in inflammatory arthritis, osteolysis, especially in combination with adenosine
With a grant from the ACR’s Rheumatology Research Foundation, Nancy J. Olsen, MD, hopes to discover how methotrexate interacts with immune system cells and ultimately helps to control the system’s attack on joints
For further reading
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.